India, Feb. 12 -- Tivic Health Systems, Inc., (TIVC) Wednesday announced the acquisition of global exclusive license rights from Statera Biopharma Inc. (STAB) to the phase 3 Toll-like Receptor 5 or TLR5 agonist Entolimod for the treatment of acute radiation syndrome or ARS.
In the pre-market hours, shares of Tivic are surging more than 71 percent at $0.40 on 140,007 shares in
The licensing agreement accelerates Tivic's transformation into a diversified therapeutics company and the late-stage product is target to a potential FDA approval within 24 months.
The company has also acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Jennifer Ernst, CEO of Tivic...